Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Hormones

Immunomodulating Agents

20 breast cancer patients who performed radiotherapy treatment

maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.

healthy women with +/- 5 years compared to breast cancer patients age

blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.

blood samples collection

Alessandra Franzetti Pellanda, MD

Radiation applied to the preserved breast during radiotherapy treatment activates numerous molecular cascades in tumor bed adjacent cells causing an inflammatory state. During this process, pre-clinical studies demonstrated CD11b + and CD11b+cKit+cells mobilization in the blood. These cells are involved in numerous processes during tumor progression/control and metastases development. The expected results in clinical setting allow us to investigate the development of innovative therapeutic and monitoring strategies. The clinical repercussions would consist in identifying new predictive and prognostic targets in breast cancer.

Every year, around one million women are newly diagnosed with breast cancer. Early screening and adjuvant treatments with curative intent such as radiotherapy, hormone therapy, chemotherapy, immunotherapy, have reduced the incidence of breast cancer specific mortality. Despite this, breast cancer remains the main cause of cancer mortality in Europe. The primary cause is due to metastases development in different organs, such as lung, liver, bones and brain. A significant decrease in mortality in breast cancer patients is likely to be achieved by preventing the formation of metastases or by implementing the efficacy of their treatment. Radiotherapy is one of the pillars of breast cancer adjuvant treatments with important survival benefits.

Mutual and dynamic communications between tumor cells and the tumor microenvironment (TME) influence the development and evolution of the tumor as well as the appearance of distant metastases. The mediators of the immune and inflammatory response that constitute TME, as well as mediators of tumor progression, are also considered "targets" of future therapeutic strategies.

Radiation applied to the preserved breast during radiotherapy treatment activates numerous molecular cascades in tumor bed adjacent cells causing an inflammatory state. During this process, pre-clinical studies demonstrated CD11b + and CD11b+cKit+cells mobilization in the blood. These cells are involved in numerous processes during tumor progression/control and metastases development. The results allow us to investigate the development of innovative therapeutic and monitoring strategies. The clinical repercussions would consist in identifying new predictive and prognostic targets in breast cancer.

Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients

Effects of Adjuvant Radiotherapy on Bone-marrow Derived and Immune Cells in Breast Cancer Patients

validate the hypothesis that adjuvant radiotherapy in breast cancer modulates the frequency of CD11b⁺cKit⁺ cells in peripheral blood and / or gene expression in circulating CD11b⁺ cells, evaluating their trend at different time points compared to radiotherapy treatment.

validate the hypothesis that adjuvant radiotherapy alters in a potentially predictive way the frequency of CD11b⁺cKit⁺ cells in peripheral blood and / or gene expression in circulating CD11b⁺ cells.

Curzio Rüegg, MD, Head of Department, University of Fribourg

Swiss National Science Foundation

Tsoutsou Pelagia MD, Head of Radation Therapy Department

Clinica Luganese Moncucco

Head of Radiation Therapy

Genetic analysis will be performed in patients who got a successful PDX

Serology and genetic analyses will be performed in patients blood samples

Judith PASSILDAS, PhD

Judith PASSILDAS JAHANMOHAN, PhD

Xavier DURANDO, Professor

Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.

The intervention consists in the realization of additional blood samples to carry out serologies and genetic analyses

Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer

A Prospective Study of Xenografts Development From Samples Taken From Surgical Specimens of Patients With Triple Negative or Luminal B Breast Cancer

PDX will be realized from patient tumor by transplanting a small fragment in a nude mouse. Once the tumor is enough grown up, the tumor is extracted to repeat this step 3 times until we get the fourth PDX with a successful tumor growth.

Comparaison of initial tumor histological subtype with PDX histological subtype

Comparaison of initial tumor expression of estrogen receptors with PDX expression of estrogen receptors

Comparaison of initial tumor expression of progesterone receptors with PDX expression of progesterone receptors

Comparaison of initial tumor's ERBB2 gene amplification status with PDX's ERBB2 gene amplification status

Comparaison of initial tumor expression of androgen receptors with PDX expression of androgen receptors

Comparaison of initial tumor molecular expression with PDX molecular classification (luminal A, luminal B, HER2 enriched or triple negative)

Comparaison of genetic alterations between intial tumor, PDX and blood sample

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients	NCT04002570	Breast Cancer	blood samples c...	18 Years - 75 Years	Clinica Luganese Moncucco
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer	NCT04133077	Breast Cancer F...	blood samples c...	18 Years -	Centre Jean Perrin
Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients	NCT04002570	Breast Cancer	blood samples c...	18 Years - 75 Years	Clinica Luganese Moncucco

Spots Global Cancer Trial Database for blood samples collection